BioCardia (BCDA) announced the first patient enrolled at University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
- BioCardia’s CardiAMP Heart Failure II Trial: A Promising Update for Investors
- BioCardia’s Innovative Stem Cell Therapy Trial for Heart Failure: Key Updates and Market Impact
- BioCardia Sets Record Date for Annual Meeting
- BioCardia Regains Nasdaq Compliance, Secures Continued Listing
- BioCardia regains compliance with Nasdaq listing requirements